Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPSZacks Investment Research • 01/30/25
Dividends And Dynamite: 10 High-Yield Blue-Chip Bargains You Don't Want To MissSeeking Alpha • 01/30/25
PFE Stock Rises on Reports of Averting Proxy Fight With Activist InvestorZacks Investment Research • 01/28/25
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers SymposiumBusiness Wire • 01/28/25
Pfizer's Conditionally Approved Braftovi Combo Therapy Regime Shows Improved Response In Colorectal Cancer PatientsBenzinga • 01/27/25
Pfizer Jumps After Avoiding Proxy Fight With Activist Investor Starboard — For NowInvestors Business Daily • 01/27/25
5 Large Cap Growth Stocks With Dividend Yields Up to 8% Are Too Cheap to Ignore24/7 Wall Street • 01/27/25
Inflation Just Won't Go Away: Stick With These 5 High-Yield Dividend Giants24/7 Wall Street • 01/25/25
Pfizer's BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal CancerBusiness Wire • 01/25/25
Peri-implantitis Market Research 2025-2030: Analysis of Growth Trends and Leading Competitors, Featuring Pfizer, Cadila Pharmaceuticals, GaronitPharma, Basic Pharma Life Science, Prachi Pharmaceuticals & MoreGlobeNewsWire • 01/23/25
4 Ultra-Safe Dividend Giants That Pay More Than the 10-Year US Treasury Note24/7 Wall Street • 01/22/25
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?CNBC • 01/21/25